U.S. Markets open in 3 hrs 30 mins

Diffusion Pharmaceuticals Inc. (DFFN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5150+0.0043 (+0.84%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.5107
Open0.5105
Bid0.5050 x 900
Ask0.5161 x 1000
Day's Range0.5020 - 0.5159
52 Week Range0.4600 - 1.8500
Volume392,063
Avg. Volume1,544,236
Market Cap52.481M
Beta (5Y Monthly)1.59
PE Ratio (TTM)N/A
EPS (TTM)-0.2760
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
  • Simply Wall St.

    We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Diffusion Pharmaceuticals Issues Letter to Shareholders

    Figure 1. Effects of TSC on transcutaneous oxygen pressure (tcpO2). The graph was created by subtracting the median placebo response from the dose and time matched median TSC response. CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert C

  • GlobeNewswire

    Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference

    Conference to Take Place Virtually, September 13-15, 2021CHARLOTTESVILLE, Va., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference taking